ImmuneOnco banks on cutting-edge cancer drugs to attract IPO cash
The biopharma wants to use IPO proceeds to bring its cancer immunotherapies to market, having already built a lofty valuation with backers such as Eli Lilly Key Takeaways: ImmuneOnco’s main…
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
- PegBio aims to bulk up its finances to deliver weight-loss drugs
